Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 9/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | FASN | P49327 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL91405 | 0.86 | HRH4 (0.55) | HRH4ALDH1A1SMN1; SMN2NPSR1MAPT | |
| SCHEMBL84443 | 0.81 | HRH4 (0.44) | HRH4KDM4EALDH1A1SMN1; SMN2MAPK10 | |
| SCHEMBL17700283 | 0.81 | NPSR1 (0.44) | HRH4ALDH1A1SMN1; SMN2NPSR1MAPT | |
| SCHEMBL15185770 | 0.80 | HRH4 (0.43) | HRH4KDM4EALDH1A1SMN1; SMN2MAPK10 | |
| SCHEMBL91477 | 0.79 | ACACB (0.51) | HRH4NPSR1FASNLMNA | |
| SCHEMBL17353594 | 0.77 | ALDH1A1 (0.52) | HRH4KDM4EALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL91483 | 0.76 | FASN (0.42) | HRH4SMN1; SMN2NPSR1MAPTCYP2C9 | |
| SCHEMBL91404 | 0.76 | BRAF (0.47) | — | |
| SCHEMBL13218581 | 0.76 | HRH4 (0.43) | HRH4ALDH1A1SMN1; SMN2NPSR1MAPT | |
| SCHEMBL91473 | 0.76 | NPSR1 (0.49) | ALDH1A1SMN1; SMN2NPSR1MAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | HRH4 2437/4885KDM4E 3041/4885ALDH1A1 3257/4885 |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | BRAF, RAF1, HRAS | HRH4 3096/4885KDM4E 2526/4885ALDH1A1 2358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.